⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

April 2, 2024Open Access

Figure S9 from ADCT-602, a Novel PBD Dimer–containing Antibody–Drug Conjugate for Treating CD22-positive Hematologic Malignancies

Francesca Zammarchi Karin Havenith Nikoleta Sachini Narinder Janghra Simon Chivers Esohe Idusogie Eugenio Gaudio Chiara Tarantelli François Bertelli Kathleen Santos Peter Tyrer Simon Corbett Filippo Spriano Gaetanina Golino Luciano Cascione Francesco Bertoni John A. Hartley Patrick H. van Berkel

View Full Paper

Ask AI

Bookmark

Share

Abstract

Supplementary Fig. S9. In vitro cytotoxicity of B12-C220-SG3249 following pretreatment with chidamide for 7 days (Ramos, TMD8, and SU-DHL-4 cell lines).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Zammarchi et al. (2024) studied this question.

synapsesocial.com/papers/68e70c5ab6db643587686136 https://doi.org/10.1158/1535-7163.25523292.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S3 from ADCT-602, a Novel PBD Dimer–containing Antibody–Drug Conjugate for Treating CD22-positive Hematologic Malignancies2024
2Figure S1 from ADCT-602, a Novel PBD Dimer–containing Antibody–Drug Conjugate for Treating CD22-positive Hematologic Malignancies2024
3Figure S5 from ADCT-602, a Novel PBD Dimer–containing Antibody–Drug Conjugate for Treating CD22-positive Hematologic Malignancies2024
4Figure S2 from ADCT-602, a Novel PBD Dimer–containing Antibody–Drug Conjugate for Treating CD22-positive Hematologic Malignancies2024
5Figure S8 from ADCT-602, a Novel PBD Dimer–containing Antibody–Drug Conjugate for Treating CD22-positive Hematologic Malignancies2024